Researchers propose 'A×G×E×D' bioengineering framework to standardize human cardiac aging models

A newly proposed bioengineering framework integrating age, genetics, environment, and drug exposure (A×G×E×D) provides a standardized, human-relevant path to model cardiac aging and evaluate long-term drug cardiotoxicity.

A perspective published in JCI Insight by researchers from the University of Pittsburgh and Carnegie Mellon University introduced the A×G×E×D framework, mapping the interactions of Age (A), Genetics (G), Environment (E), and Drug (D) exposure in cardiac aging.

The authors highlighted the integration of human induced pluripotent stem cell-derived (hiPSC-derived) 3D microtissues and advanced microphysiological systems (MPS) to capture tissue-level aging trajectories.

The paper detailed the application of flexible bioelectronics, including kirigami-inspired stretchable mesh arrays and high-density multielectrode arrays (incorporating over 128 electrodes), to achieve long-term, non-disruptive electrophysiological mapping in in vitro systems.

Preclinical cardiac models are heavily reliant on mice, which differ structurally and electrophysiologically from humans, displaying heart rates of 500 to 600 beats per minute compared to human heart rates of 60 to 100 beats per minute.

Standard 24- to 48-hour in vitro drug exposure assays fail to capture late-emerging cardiotoxicities or complex age-drug interactions, which require stable, long-term monitoring technologies to resolve.

Developing human-centric tissue platforms allows researchers to observe dynamic cellular interactions, somatic mutational burdens, and the 12 hallmarks of aging directly in mature human cardiac tissue contexts.

The regulatory push from the FDA Modernization Act encourages the adoption of human-relevant alternative testing platforms, driving the commercial value of highly characterized 3D organ-on-chip systems.

The integration of multimodal biosensors (tracking metabolites like glucose, lactate, and ATP) and machine learning models provides longevity developers with quantitative, continuous aging scores to screen senolytic and cardioprotective candidates.

Standardized human-relevant models help drug developers bypass low-translation rodent studies, potentially reducing clinical attrition for cardiovascular therapeutics targeted at older cohorts.

The implementation of multi-omic benchmarking protocols to align in vitro phenotypic timelines with primary human donor heart tissue datasets.

Technological modifications aimed at sustaining the viability and baseline stability of immunocompetent 3D co-cultures beyond the current technical limit of 90 to 120 days.